Combined FGFR and Akt Pathway Inhibition Abrogates Growth of FGFR1 Overexpressing EGFR-TKI-Resistant NSCLC Cells

Researchers identified increased fibroblast growth factor receptor 1 (FGFR1) expression and Akt activation across erlotinib, gefitinib, and osimertinib EGFR-tyrosine kinase inhibitor (TKI)-resistant cell line models.